Overview

Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia

Status:
Completed

Trial end date:
2008-09-01

Target enrollment:

Participant gender:

Summary

The objective of this study is demonstrate efficacy and a dose-response in the treatment of acute exacerbation of schizophrenia in comparison to placebo.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Aripiprazole